Statistical Evaluation and Analysis of Regional Interactions: The PLATO Trial Case Study

Statistics in Biopharmaceutical Research

Volumn 5, Issue 2, 2013, Pages 91-101

  Carroll, Kevin J ^a   Fleming, Thomas R ^b  

^a Independent Statistical Consultant   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Effect modifiers; Multiregional trials; Regional interactions

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANALYSIS OF REGIONAL INTERACTION; ARTICLE; BIOGEOGRAPHIC REGION; CASE STUDY; DRUG MEGADOSE; HUMAN; HYPOTHESIS; INTERNAL CONSISTENCY; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; UNITED STATES;

EID: 84880994189     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2013.783878     Document Type: Article

References (18)

1. AstraZeneca. 2010. Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM220197.pdf
2. Center for Drug Evaluation and Research. 2011a. "Brilinta, Product Label," Food and Drug Administration. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000Lbl.pdf
3. Center for Drug Evaluation and Research. 2011b. "Brilinta, Summary Review," Food and Drug Administration. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000SumR.pdf
4. Center for Drug Evaluation and Research. 2011c. "Brilinta, Statistical Review," Food and Drug Administration. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000StatR.pdf
5. European Medicines Agency. 1998. "ICH E5 Ethnic Factors in the Acceptability of Foreign Clinical Data," European Medicines Agency. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf
6. Fleming, T. R. 1995. Interpretation of Subgroup Analyses in Clinical Trials. Drug Information Journal, 29: 1681S - 1687S.
7. Fleming, T. R. 2010. Clinical Trials: Discerning Hype from Substance. Annals of Internal Medicine, 153: 400 - 406.
8. 12 Receptor Blockade Supplied by Either Ticagrelor or Prasugrel. Journal of Thrombosis and Haemostasis, 9: 2103 - 2105.
9. Mahaffey, K. W. 2011. Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation, 124: 544 - 554.
10. Ministry of Health, Labour and Welfare, Pharmaceutical and Food Safety Bureau, Director of Evaluation and Licensing Division. 2007. Basic Principles on Global Clinical Trials. available at www.pmda.go.jp/operations/notice/2007/file/0928010-e.pdf
11. O'Neill, R. 2009. Statistical Issues in Multiple-Regional Clinical Trials. FDA/Industry Statistics Workshop. available at http://www.amstat.org/meetings/fdaworkshop/index.cfm?fuseaction=AbstractDetails&AbstractID=300578
12. Quan, H. 2012. Empirical Shrinkage Estimator for Consistency Assessment of Treatment Effects in Multiregional Clinical Trials. Statistics in Medicine. published online August 1. Available at http://onlinelibrary.wiley.com/doi/10.1002/sim.5543/pdf
13. Senn, S. and Harrell, F. 1997. On Wisdom After the Event. Journal of Clinical Epidemiology, 50: 749 - 751.
14. Simon, R. 2002. Bayesian Subset Analysis: Application to Studying Treatment-by-Gender Interactions. Statistics in Medicine, 21: 2909 - 2916.
15. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. 2008. Guidance for Industry Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. available at http://www.fda.gov/downloads/Drugs/GuidanceCom plianceRegulatoryInformation/Guidances/UCM071627.pdf
16. Wallentin, L. 2009a. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes. New England Journal of Medicine, 361: 1045 - 1057.
17. Wallentin, L. 2009b. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes. New England Journal of Medicine, 361: 1045 - 1057. Supplementary appendix available at http://www.nejm.org/doi/suppl/10.1056/NEJMoa0904327/suppl_file/nejm_wallentin_1045sa1.pdf
18. Warner, T. D., Nylander, S. and Whatling, C. 2011. Anti-Platelet Therapy: Cyclo-oxygenase Inhibition and the Use of Aspirin With Particular Regard to Dual Anti-platelet Therapy. British Journal of Clinical Pharmacology, 72: 619 - 633.